Dendritic cell-based immunotherapy induces transient clinical response in advanced rat fibrosarcoma - comparison with preventive anti-tumour vaccination

0333752 - ÚMG 2010 RIV CZ eng J - Článek v odborném periodiku
Kučera, A. - Pýcha, K. - Pajer, Petr - Špíšek, R. - Škába, R.
Dendritic cell-based immunotherapy induces transient clinical response in advanced rat fibrosarcoma - comparison with preventive anti-tumour vaccination.
Folia Biologica. Roč. 55, č. 4 (2009), s. 119-125. ISSN 0015-5500. E-ISSN 0015-5500
Výzkumný záměr: CEZ:AV0Z50520514
Klíčová slova: dendritic cells * immunotherapy * cancer immunotherapy * chemotherapy
Kód oboru RIV: EB - Genetika a molekulární biologie
Impakt faktor: 0.924, rok: 2009

We describe models of preventive and therapeutic vaccination of sarcoma-bearing rats with dendritic cells (DC) presenting tumour antigens from killed tumour cells, together with characteristics of DC-based vaccine and its capacity to induce anti-tumour immune response both in vitro and in vivo. We show that preventive vaccination efficiently prevents tumour growth. However, vaccination of rats with established tumours did not lead to eradication of the tumours – despite induction of a vigorous immune response and transient decrease in tumour progression, tumours eventually resumed growth. Preventive and therapeutic DC-based vaccination induced strong tumour-specific T-cell response. These results argue for the timing of cancer immunotherapy to the stages of low tumour load. Immunotherapy at the stage of minimal residual disease, after reduction of tumour load by other modalities, should offer a better clinical benefit to cancer patients than immunotherapy of metastatic disease.
Trvalý link: http://hdl.handle.net/11104/0178670